Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression by Reid, Anna L et al.
Edith Cowan University 
Research Online 
ECU Publications 2013 
1-1-2013 
Markers of circulating tumour cells in the peripheral blood of 
patients with melanoma correlate with disease recurrence and 
progression 
Anna L. Reid 
Edith Cowan University 
M Millward 
Robert Pearce 
Edith Cowan University 
M Lee 
M Frank 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworks2013 
 Part of the Hematology Commons 
10.1111/bjd.12057 
This is the pre-peer reviewed version of the following article: Reid, A. L., Millward, M., Pearce, R. , Lee, M., Frank, M., 
Ireland, A., Monshizadeh, L., Rai, T. , Heenan, P., Medic, S. , Kumarasinghe, P., & Ziman, M. R. (2013). Markers of 
circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and 
progression. British Journal of Dermatology, 168(1), 85-92., which has been published in final form at 
https://doi.org/10.1111/bjd.12057. This article may be used for non-commercial purposes in accordance with 
Wiley Terms and Conditions for Self-Archiving. 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworks2013/477 
Authors 
Anna L. Reid, M Millward, Robert Pearce, M Lee, M Frank, A Ireland, L Monshizadeh, Tapan Rai, P Heenan, 
Sandra Medic, P Kumarasinghe, and Melanie R. Ziman 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworks2013/477 
Markers of circulating tumour cells expressed in melanoma patients, A. Reid et al. 
1 
 
TITLE: Markers of circulating tumour cells in the peripheral blood of melanoma 
patients correlates with disease recurrence and progression. 
A.L. Reid*, M. Millward†, R. Pearce*, M. Lee†, M.H. Frank‡, A. Ireland†, L. 
Monshizadeh†, T. Rai*, M. Ziman*+  
* School of Medical Sciences, Edith Cowan University, Perth, WA, Australia, †Department of Medicine, 
University of Western Australia, Crawley, Australia, ‡Transplantation Research Center, Children's Hospital 
Boston and Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  +
School of 
Pathology and Laboratory Medicine, University of Western Australia, Crawley, Australia 
 
 Correspondence 
Associate Professor Melanie Ziman  
Director ECU Melanoma Research Foundation  
Edith Cowan University (ECU) 
 270 Joondalup Drive, Joondalup, Perth, WA 6027  
Ph: +61 - 8 – 63043640  
Fax: +61 -8- 63042626  
Mob: +61 (0) 419929851  
E-mail: m.ziman@ecu.edu.au 
 
 
 
Funding sources- Ziman, NHMRC Application number 1013349; Cancer and Palliative 
Care Research and Evaluation Unit WAPCN Small Grants 2010/11; and  Cancer 
Council of WA Research Grant.  
Frank, Grant support MHF: National Institutes of Health (USA) grant numbers 
5R01CA113796, 1R01CA138231 and 2P50CA093683. 
 
 
Conflict of interest 
None declared 
 
Manuscript word count – Questions: 73 & 80 words, Abstract: 239 words, Body: 3,387 
Manuscript table count –5 tables, 1 figure, 1 figure legend and 3 supplementary tables 
Markers of circulating tumour cells expressed in melanoma patients, A. Reid et al. 
2 
 
Questions 
 
What is already known about this topic? 
 Considerable effort has been devoted to developing an effective non-invasive method 
of monitoring disease progression and outcome among cancer patients. One method is 
multimarker qRT-PCR used to detect circulating tumour cells in patient blood.  In 
breast, colorectal and prostate cancer circulating tumour cells correlate with both 
disease progression and poor treatment outcome. Circulating cell analysis in 
melanoma has had varied success; despite the capacity to detect cells the appropriate 
markers remain undefined. 
 
What does this study add? 
 This is the first application of ABCB5 as a marker of circulating melanoma cells, 
incorporated into a multi marker qRT-PCR test of melanoma patient blood. Expressed 
by a subset of melanoma cells with a stem cell phenotype, its detection in this study, 
along with MLANA a melanocyte marker, correlated with disease recurrence, 
suggesting both stem and non-stem cell phenotypes are present in patient peripheral 
blood. MCAM expression is shown for the first time to correlate with negative 
treatment outcomes.  
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ABSTRACT 
Background: Multimarker quantitative real-time PCR (qRT-PCR) represents an effective 
method for detecting circulating tumour cells in the peripheral blood of melanoma patients.  
Objectives: The aim of this study was to investigate whether the phenotype of circulating 
melanoma cells represents a useful indicator of disease stage, recurrence and treatment 
efficacy. 
Methods:  Peripheral blood was collected from melanoma patients (n=230) and healthy 
controls (n=152) over a period of three years and nine months. Clinical data and blood 
samples were collected from patients with primary melanoma (early stages 0-II (n=154)) and 
metastatic melanoma (late stages III-IV (n=76)). Each specimen was examined by qRT-PCR 
analysis for the expression of five markers: MLANA, ABCB5, TGFβ2, PAX3d and MCAM.  
Results: Two hundred and twelve melanoma patients (92%) expressed markers in their 
peripheral blood. Two markers, MLANA and ABCB5, had the greatest prognostic value, and 
were identified as statistically significant among patients who experienced disease recurrence 
within our study period, being expressed in 45% (MLANA) and 49% (ABCB5) of patients 
with recurrence (p=0.001 & p=0.031). For patients administered non-surgical treatments, 
MCAM expression correlated with poor treatment outcome.  
Conclusion:   
Circulating tumour cells were detectable at all stages of disease and long after surgical 
treatment even when patients were considered disease free. Specifically, expression of 
ABCB5 and MLANA had significant prognostic value in inferring disease recurrence while 
MCAM expression was associated with poor patient outcome after treatment, confirming 
multimarker qRT-PCR as a potential technique for monitoring disease status. 
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Introduction 
Cutaneous melanoma is a tumour originating from normal skin melanocytes. Global 
incidence of melanoma is increasing
1
, with an estimated 70,230 new cases annually in the 
USA 
2
. Melanoma has a high metastatic potential 
3
 and metastatic melanoma is difficult to 
treat . It is important therefore to find methods of detecting melanoma spread at early stages 
for more accurate treatment and prediction of prognosis. 
A staging system was devised by the American Joint Committee on Cancer (AJCC) based on 
histological features of the primary lesion, and the presence of nodal and/or systemic 
metastases in advanced disease 
3
. Due to increased awareness, most patients present with 
thin, localised melanoma which is usually curable by surgical resection. However, 
approximately 5% of patients with lesions <1 mm thick, 25-40% with 2 to 4 mm lesions and 
50-75% with lesions > 4 mm develop metastatic disease and die within ten years 
3
. Patients 
diagnosed with regional and distant metastases have 10 year survival rates of 64% and 16% 
respectively 
4
.  
Patients may suffer relapse following disease free periods of ten years or more 
5,6
. Evidently 
then, diagnosing patients as clinically disease free after surgical removal of early stage 
melanomas, may be inaccurate, since tumour cells  dispersed into the bloodstream may 
remain dormant, prior to formation of distant metastases 
7
.  
Considerable research into the detection of circulating tumour cells in the blood of patients 
with breast, colorectal and prostate cancer has shown that the presence of these cells 
correlates with both disease progression and poor outcome
8-16
. For melanoma, circulating cell 
analysis has not been successfully utilised clinically. Although several articles have indicated 
their usefulness
17-22
, markers and methodology remain controversial. Moreover, it is unclear 
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whether circulating melanoma stem cells are prognostic 
23
 or whether all circulating  
melanoma cells have metastatic potential 
24
.  
Here we used multimarker qRT-PCR to investigate the phenotype of circulating cells in 
melanoma patients. Given qRT-PCR sensitivity, it is suitable for assessment of rare 
circulating melanoma cells 
25
 and multiple markers are essential given the heterogeneous 
nature of melanoma cells 
18,26
. Our markers included melanocyte (PAX3d 
27
 and MLANA 
28
),  
tumour (TGFβ2 29 and MCAM 30) and stem cell (ABCB5 31) markers. PAX3 regulates 
melanocytic development 
32-34
, and the PAX3d isoform is highly expressed in melanoma 
35
. 
ABCB5 a stem cell marker, marks a subset of rare, chemoresistent melanoma stem cells 
24,31,36
 , while MCAM is a marker of melanoma tumour progression 
34
.   
We show that circulating tumour cells are detectable at all stages of disease and persist long 
after treatment.  Certain circulating cells, specifically those marked by MCAM expression, 
correlated with a poor treatment outcome, while ABCB5 and MLANA, correlated with 
disease progression and could aid in monitoring disease status.  
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Material and Methods 
Patient cohort  
Patient (230) and healthy control (152) participants provided written consent. Patients were 
recruited from the Medical Oncology Department of Sir Charles Gairdner Hospital and the 
Perth Melanoma Clinic at Hollywood Hospital (Perth, Western Australia) and consisted of 81 
females and 149 males aged 24 – 96 (mean 69 years) while the aged matched, healthy cohort, 
recruited from the general population, contained 86 females and 66 males aged 18-99 (mean 
51 years). The Human Research Ethics Committees of Edith Cowan University (No. 2932) 
and Sir Charles Gairdner Hospital (No. 2007-123) approved the study. 
The study included 154 patients with primary cutaneous melanoma and 76 with metastatic 
melanoma. AJCC Clinical staging categorised 16.5% of our patients as stage 0, 33.5% as 
stage I, 17% as stage II, 13% as stage III and 20% as stage IV (Table 2). Patients were 
sampled only once and clinical history recorded, however a subset of patients (n=140) were 
sampled serially throughout the 3.9 year study. Tumour burden was calculated from 
pathology reports for a subset of 32 patients, by calculating the sum of maximal tumour 
diameters for all tumours within the patient, at the time of sampling. 
Melanoma cell lines 
Human melanoma cell line A2058 cells (EACC: 91100402), were grown in DMEM media 
containing 10% heat inactivated foetal bovine serum (Invitrogen) in a T75-cm
2
 flask 
(Greiner) until cells were ~70% confluent.  
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Blood Collection, RNA Isolation and Amplification Protocols 
At venipuncture, the first 4 mL of  blood was discarded to avoid epithelial contamination 
37
. 
2.5mL of whole blood was then collected into a PAXgene Blood RNA Tube (PreAnalytiX), 
containing RNA stabilisers 
38
.  
Total RNA was isolated using the PAXgene Blood RNA kit (Qiagen) and DNase treated 
(DNA-free Kit, Ambion).  RNA was quantified and the integrity was qualified (Agilent 2100 
Bioanalyser, Agilent Technologies). Samples with insufficient RNA levels (RIN <8) were 
excluded. 
Total RNA (250ng) was converted to cDNA (Omniscript Reverse Transcriptase Qiagen). 
Each reaction (20 µL), contained, 2µL of RT Buffer (1x), 2 µL of dNTPs (5mM), 2 µL of 
oligo (dT) primer (0.4 ug/ul), 1 µL of RNase inhibitor (10U/ µL) (Invitrogen) and 1 µL of 
omniscript reverse transcriptase (4U/ µL). Incubation was 37 °C for 1 hour; then 5 mins at 95 
°C and included a no template control (NTC). Quantitative RT-PCR assays assessed the 
number of mRNA transcripts (level of expression) for six genes, MLANA, ABCB5, TGFβ2, 
PAX3d, MCAM and GAPDH. Each 15 µL reaction contained 1µL of cDNA template, 1x 
SYBR GreenER qPCR SuperMix (Invitrogen) and 200nM of primer (Supplementary Table 
1). Using an iCycler iQ5 Real-Time Thermocycler (BIO-RAD) incubation was as per the 
manufacturer’s instructions.  
 
To prevent contamination all PCR reactions contained Uracil-N-glycosylase to prevent 
reamplification of carryover PCR products 
39
 and  different steps were performed in separate 
UV treatable areas. Tm determination and gel electrophoresis confirmed the expected size 
and identity of PCR products. 
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GAPDH, our internal reference for RT efficiency, is not up regulated in melanoma tissues or 
cultured cells relative to normal samples 
40
; samples with insufficient levels were excluded. 
Every assay included a standard curve, negative controls (NTC and reverse transcription 
control), positive control (A2058 cell line) and cDNA from a single healthy control.  
Standard Curve 
A standard curve to quantify mRNA copy number, was constructed using larger PCR 
products that included the target sequence used in qRT-PCR assays. For each standard, an 
end point PCR primer set was designed (Supplementary Table 2). A2058 cDNA, synthesized 
from 250ng of RNA, was used as a template. Using a Taq DNA polymerase kit (Qiagen), 
each 20µL reaction consisted of 1x Coral Load buffer, 0.2mM of each dNTP, 2.5U of Taq 
DNA polymerase, 1µL cDNA and 200nM of primer. Incubation involved: 94°C for 5 
minutes, then 45 cycles of 94°C for 30 seconds, then 55°C for 30 seconds and 72°C for 1 
minute. PCR products were purified after  agarose gel electrophoresis using the freeze-
squeeze method 
41
. Resulting stock template solutions were quantified by spectrophotometric 
analysis (Nanodrop, Thermo Scientific) and diluted into eight tenfold serial dilutions (10
1
 -
10
8
 copies/µL) from which a standard curve for each target was generated on the iCycler iQ5 
Real-Time Thermocycler. Amplification efficiency of our target genes were between 96.4 
and 100%. Samples were analysed in duplicate with averaged cT values used for relative 
quantification. Relative mRNA copies for each transcript were calculated by dividing 
absolute mRNA copies of the target by that of GAPDH.   
Statistical Analysis                        
Pearson chi-square test and Fishers exact test were used to examine statistical significance of 
marker expression between patient groups and controls. The Cochrane-Armitage trend test 
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examined correlation between clinical stage, Clark level and/or expression level. Positive and 
negative predictive values were calculated to examine the sensitivity of our test.  
The relationship between level of marker expression and stage or presence of disease, was 
investigated by Mann-Whitney U test and Kruskal-Wallis H test. Generalised linear 
modelling was used to examine marker consistency. SPSS was used for analysis and 
differences of p<0.05 were considered statistically significant.  
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 Results 
Multimarker RT-PCR analysis was used to estimate the phenotype and quantity of circulating 
cells in patient blood. Marker positivity and level of expression were analysed for correlation 
with disease presence, stage, recurrence and treatment outcome.  
Marker Expression in Patient Blood Relative to Controls: 
Melanoma patients (92%, n=212) were significantly more likely to express a melanoma cell 
marker in blood than were controls (59%, n=89) (p= 0.000, Odds ratio = 4.206, 95% CI 
2.305-7.676). The number of markers expressed by participants was important, with 83% 
(n=126) of healthy controls expressing either no marker or just one marker, in contrast to 
melanoma patients, who were highly likely to express two or more markers (72%, 
n=165)(p=0.012)(Table 1). The positive and negative predictive value of expressing a 
marker, was 70% and 78% respectively. Expression of two or more melanoma markers 
improved the positive predictive value to 86%, with a negative predictive value of 66%.      
To identify the most informative markers, we analysed expression incidence of each marker 
in patients. MLANA, ABCB5, MCAM, PAX3d, and TGFβ2 were detected in 30% (n=68), 
40% (n=90), 47% (n=108), 40% (n=91), and 66% (n=152) of melanoma patients, 
respectively.  
Marker Expression in Patients Relative to Clinical Stage: 
To assess marker utility, we analysed marker expression relative to clinical stage. MLANA 
and ABCB5 were significantly more likely to be expressed in late stage patients (Stages III-
IV) (42% and 51%) than in early stage patients (0-II) (23% and 33%) (p=0.003 and p=0.006). 
No other markers appeared to be stage related (Table 2). 
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Clinical factors including primary location, Clark level, Breslow thickness and ulceration did 
not correlate with marker expression (Table 3). 
Pearson chi-square test was used to analyse whether the incidence of marker expression in 
patient blood samples taken within one month of clinical diagnosis differ from samples taken 
at times greater than one month following diagnosis. For most markers, expression did not 
differ between samples taken at times less than and greater than one month following 
diagnosis.  TGFβ2 however, was expressed slightly more frequently in samples obtained 
more than a month following diagnosis (47%, n=187) relative to samples collected within in 
the first month following diagnosis (32%, n=50) (p=0.001). Samples taken at times greater 
than one month after diagnosis were as likely to express a marker (79%, n=311), than 
samples taken within the first month following diagnosis (71%, n=110).  
Marker Expression Correlates to Disease Recurrence: 
To investigate the prognostic value of our markers, the relationship between marker 
expression and disease recurrence was analysed. Seventy three patients (32%) experienced 
recurrence during our study and in these patients, both MLANA and ABCB5 were expressed 
significantly more frequently (45%, n=33 and 49%, n=36) than in patients without recurrence 
(23%, n=35, 34%, n=54) (p=0.001 and p=0.031) (Table 4). Patients with recurrence 
expressed 5 markers more commonly (8%, n=6) than patients who experienced no recurrence 
during our study (1%, n=2) (p=0.013). Patients with recurrence during our study were more 
likely to express both ABCB5 and MLANA (26%, n=19) than patients without recurrence 
during the study period (10%, n=15) (p=0.002). Co-expression of MLANA and ABCB5 
produced a positive predictive value of 56% and a negative predictive value of 72%.  
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When divided into stages, 48% of stage III-IV patients with recurrence (n=29) expressed 
MLANA compared to only 19% of stage III-IV patients without recurrence (n=3) (p=0.033). 
There was no correlation between MLANA expression and recurrence in early stage (0-II) 
patients. Analysing the presence and level of markers relative to time since diagnosis in 
patients who developed recurrence during our study, revealed markers were present in patient 
blood at all stages, many years after diagnosis or surgical removal of the primary tumour, 
even when there were no clinical signs of disease (Table 4). 
Marker Expression in relation to Tumour Burden: 
To examine if marker expression correlated with tumour burden, stage III-IV patients were 
divided into those with one metastasis (n=16) (mean of tumour diameter: 19.8mm±13.2mm 
(mean±SD)) or multiple metastases (mean of sum of tumour diameter: 76.5mm±36.06mm) at 
the time of sampling (n=16). Only MCAM expression was significantly related to tumour 
burden, with the level of expression greater among stage III-IV patients with multiple 
metastases (1.23±1.66, n=4) than in those with only a single metastasis (0.67±0.49 
(mean±SD), n=8,) (p=0.027). 
Among stage III-IV patients, the surgical removal of a clinically measureable metastatic 
tumour also influenced marker expression. MLANA and Pax3d were expressed less 
frequently in patients following the surgical removal of a clinically measureable metastatic 
tumour (18%, n=29; 19%, n=30), compared to patients with an existing tumour burden (48%, 
n=16; 42%, n=14) (p=0.000 & p=0.003, respectively). A significant reduction in the level of 
ABCB5 expression was observed in stage III-IV samples corresponding to the removal of a 
clinically measureable metastasis (0.19±0.79), compared to samples with an existing tumour 
burden (0.22±0.42)(p=0.011).         
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Marker Expression in Relation to Clinical Treatment: 
To analyse the effect of non-surgical treatment on circulating tumour cell phenotypes, marker 
expression was investigated in 34 patients (15%) who received non-surgical treatment. 
Treatments included: radiotherapy (n=29), interferon alfa 2b (n=5), limb infusion (n=1), 
vaccine (n=4), chemotherapy (n=9) and radio frequency ablation (RFA) (n=1).  
Three patients were sampled both before and after their non-surgical treatment, whereas the 
majority of non-surgically treated patients were sampled during or following treatment. The 
condition of two patients deteriorated post treatment, while the third remained stable (Figure 
1). Patient 1 was sampled at diagnosis of a stage III melanoma, two months prior to 
radiotherapy treatment of the left inguinal node, and expressed only ABCB5. Seventeen 
months later, with their left axilla node identified as positive, the patient gained MLANA and 
MCAM expression and the level of ABCB5 expression was maintained. No markers were 
detected in patient 2, three months prior to RFA treatment for a lung metastasis. Sampled 
three months after treatment, MLANA, ABCB5 and Pax3d were detected; the patient died 
three months later. Patient 3 had positive lymph nodes and expressed no markers the day 
before interferon alfa 2b treatment. Serial blood collections were then made at six, twelve, 
twenty-one, and twenty-six months post treatment. TGFβ2 was detected at six, and twelve 
months and TGFβ2, MCAM and ABCB5 were detected by twenty-six months with a 5 fold 
decrease in MCAM between the last two serial samples. 
The majority of the non-surgically treated stage IV samples were collected after non-surgical 
treatment (n=26). To examine whether the phenotype of circulating melanoma cells reflects 
the effectiveness of treatment, samples were divided into those from patients who had a 
negative treatment outcome (n=40) (progression and/or death) and those with a positive 
outcome (n=22) (disease remained stable or tumour size reduced). The expression of MCAM 
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was significantly more common in patients with a negative treatment outcome with 43% 
expressing MCAM (n=17), while only 9% of samples from patients with a positive outcome, 
expressed this marker (n=2) (p=0.006)(Table 5). The positive predictive value for MCAM 
expression as a marker of poor clinical outcome in patients with stage IV melanoma is 
89.5%, while the negative predictive value is 46.5%.     
                                                                                                                                                                                                                                                                                                 
Marker Consistency and Serial Blood Collection 
21.7% of all acquired blood samples had a technical repeat (second PAXgene Blood RNA 
tube) taken on the same day. Expression in these samples was highly consistent, with 70% of 
duplicate samples having identical marker expression (n=273). 
Generalised linear modelling was employed to examine serially collected samples (n=140), 
acquired for each patient at intervals of six months over a period of two years. For the 
majority of our markers, time was not a significant variable, with marker expression 
remaining consistent, regardless of sampling time and regardless of stage (Supplementary 
Table 3). For ABCB5 however, expression incidence significantly reduced over time (Wald-
Chi = 16.209, p=0.000) in stage IV patients (Odds ratio: 0.2518, p=0.000, 95% CI 0.131, 
0.483), which may represent the effect of non-surgical treatment on ABCB5 expression in 
stage IV patients.  
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Discussion: 
This study showed that a multi marker qRT-PCR test for melanoma circulating cells 
correlated with melanoma diagnosis. Very few melanoma patients expressed no markers at 
all, only 7%. A significant number of healthy controls, however also expressed one marker. 
Therefore, patients and controls are best differentiated by the number of markers expressed 
i.e. by a multi marker test.  
Multiple markers were detected at all disease stages, even in early stage patients, however the 
incidence was lower in these patients than in later stage patients. In contrast to previous 
papers 
18,42
, the levels and number of markers were not stage related, possibly related to the 
use of ABCB5 and TGFβ2, both previously unused markers of circulating tumour cells.  
TGFβ2 was the most common marker in controls, so cannot be recommended as a single 
marker for patient analysis. 
By contrast, ABCB5, described by Frank and colleagues in 2003 was a highly informative 
marker 
23,24,31,36
. ABCB5 reportedly represents a subset of melanoma cells with a stem cell 
phenotype and is thought here to represent a subset of heterogeneous circulating melanoma 
cells present at all disease stages. In this study it was identified as a potential predictor of 
active recurrence/progression events with its expression in blood correlating with disease 
recurrence and progression in patients, a finding that warrants further testing of this marker. 
This marker was detected amongst patients regardless of whether or not they were considered 
clinically disease free, indicating that these stem - like circulating cells remain for long 
periods in the blood. A role for ABCB5 cells in disease spread has been demonstrated in 
mouse -to-mouse transplantation experiments, where circulating ABCB5 expressing tumour 
cells were shown to be capable of initiating metastatic disease after transplantation into donor 
mice 
23
.   
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Besides ABCB5, MLANA expression was also a potential predictor of recurrence events in 
our patient cohort. Since ABCB5 positive cells do not co-express MLANA
24
, circulating cells 
must therefore include both stem and non-stem cell phenotypes during recurrence. This may 
reflect a change in stem cell to a non-stem cell phenotype during formation of the metastatic 
tumour
43
. Previous studies described MLANA expression as correlating with disease stage
25
, 
and in this study both MLANA and ABCB5 expression correlated with disease stage, with 
expression more common in advanced (stage III-IV) than in early stage (stage 0-II) patients. 
In fact, removal of a clinically measurable metastasis significantly reduced the expression of 
Pax3d, ABCB5 and MLANA in stage III-IV patients, signifying the importance of metastases 
in maintaining the hematogenous spread of tumour cells 
44,7
.  
Utilising these markers, circulating tumour cells were detected at all disease stages long after 
surgical treatment, even when a patient was considered clinically disease free. Thus, as found 
in previous studies of circulating tumour cells 
42,45
, the mere presence of circulating tumour 
cells does not always correlate with disease stage or metastatic recurrence, and additional 
markers are required to stratify those early stage patients likely to have disease progression.  
In our study MCAM expression correlated with increased tumour burden, a result consistent 
with recent in vivo studies with nude mice that revealed a significant correlation between 
MCAM expression and the formation of metastases 
46
. MCAM was also the most suitable 
marker for monitoring response to therapy and indicates, presumably, ineffective eradication 
of circulating melanoma cells, evidenced here by an increase in the incidence of MCAM 
expression in patients with a negative treatment outcome. MCAM expression could therefore 
be used to monitor treatment resistance or risk of relapse. Given MCAM expression is 
thought to play a role in cell-cell and cell-matrix interactions during formation of metastases, 
the expression of MCAM in circulating cells may aid in the spread of malignant melanoma 
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cells throughout the body 
7,44
. A previous study found MCAM to be a predictor of poor 
patient survival and disease prognosis 
43
.  Overall, 68% of non-surgically treated patients had 
a negative treatment outcome, highlighting the poor response rate of patients to non-surgical 
treatments and reflected here by 64% of these patients expressing MCAM. Essentially, 
MCAM expression may aid in identifying a subset of patients with metastatic disease who 
respond poorly to conventional systemic treatments and may benefit from an alternative 
treatment regime.  
Some p-values were achieved by considering several different predictors. However, 
corrections were not made for multiple comparisons because the markers were considered to 
be independent.  Moreover, even when we applied Bonferroni corrections to secondary 
hypotheses for 5 comparisons, the majority of hypotheses remained significant (p<0.01); for 
example, comparisons between early versus late disease stage (MLANA p = 0.003 and 
ABCB5 p=.006), disease recurrence (MLANA p=0.001) and negative treatment outcome 
(MCAM p=0.006) remain significant. Only the correlation of MCAM expression and tumour 
burden (MCAM p = 0.027), and ABCB5 expression in relation to recurrence (ABCB5 
p=0.031) and the surgical removal of a clinically measurable lesion (ABCB5 p=0.011) are no 
longer significant. Despite this, MCAM and ABCB5 remain valuable markers of clinical 
outcome and disease recurrence, especially ABCB5 expression in combination with 
MLANA. 
It is clear that circulating tumour cells are detectable at all stages of disease and the specific 
detection of ABCB5, MLANA and MCAM expressing tumour cells in blood may be of 
prognostic value. Importantly, we demonstrated that a qRT-PCR multi-marker blood test 
provides a suitable method from which to develop further a reliable test for monitoring 
disease status without the need for specific isolation of circulating tumour cells.   
Markers of circulating tumour cells expressed in melanoma patients, A. Reid et al. 
18 
 
Acknowledgements 
The authors thank Liz Watson, Jenny Fairweather and Katrina Burton for their assistance 
with this study. 
  
Markers of circulating tumour cells expressed in melanoma patients, A. Reid et al. 
19 
 
References 
 
1 Tucker MA. Melanoma Epidemiology. Hematology/Oncology Clinics of North America 2009; 
23: pp. 383-95. 
2 Siegel R, Ward E, Brawley O et al. Caner statistics, 2011: The impact of eliminating 
socioeconomic and racial disparities on premature cancer deaths. CA Cancer journal for 
clinicians 2011; 61: pp. 212-36. 
3 Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on 
cancer staging system for cutaneous melanoma. Journal of Clinical Oncology 2001; 19: 3635-
48. 
4 Pollack AL, Li J, Berkowitz Z et al. Melanoma survival in the United States, 1992 to 2005. 
Journal of the American Academy of Dermatology 2011; 65: pp. 78-86. 
5 Tsao H, Cosimi AB, Arthur JS. Ultra-Late recurrence (15 years or longer) of cutaneous 
melanoma. Cancer 1997; 79: pp. 2361-70. 
6 Shen P, Guenther JM, Leslie AW et al. Can elective lymph node dissection decrease the 
frequency and mortality rate of late melanoma recurrences? Annals of Surgical Oncology 
2000; 7: pp. 114-9. 
7 Stoecklein N, Hosch S, Bezler M et al. Direct genetic analysis of single disseminated cancer 
cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008; 
13: PP. 441-53. 
8 Sastre J, Maestro ML, Puente J et al. Circulating tumor cells in colorectal cancer: correlation 
with clinical and pathological variables. Annals of Oncology 2008; 19: pp. 935-8. 
9 Gaforio JJ, Serrano MJ, Sanchez-Rovira P et al. Detection of breast cancer cells in the 
peripheral blood is positively correlated with estrogen-receptor status and predicts for poor 
prognosis. International Journal of Cancer 2003; 107: pp. 984-90. 
10 Shariat SF, Kattan MW, Song W et al. Early postoperative peripheral blood reverse 
transcription PCR assay for prostate-specific antigen is associated with prostate cancer 
progression in patients undergoing radical prostatectomy. Cancer Research 2003; 63: pp. 
5874-8. 
11 Müller V, Stahmann N, Riethdorf S et al. Circulating tumor cells in breast cancer: correlation 
to bone marrow micrometastases, heterogeneous response to systemic therapy and low 
proliferative activity. Clinical Cancer Research 2005; 11: pp. 3678-85. 
12 Benoy IH, Elst H, Philips M et al. Real-time RT-PCR detection of disseminated tumour cells in 
bone marrow has superior prognostic significance in comparison with circulating tumour 
cells in patients with breast cancer. British Journal of Cancer 2006; 94: pp. 672-80. 
13 Lembessis P, Msaouel P, Halapas A et al. Combined androgen blockade therapy can convert 
RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen 
(PSMA) transcripts from positive to negative in the peripheral blood of patients with 
clinically localized prostate cancer and increase biochemical failure-free survival after 
curative therapy. Clinical Chemistry and Laboratory Medicine 2007; 45: pp. 1488-94. 
14 Pfitzenmaier J, Ellis WJ, Hawley S et al. The detection and isolation of viable prostate-specific 
antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific 
antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate 
cancer. Urologic Oncology 2007; 25: pp. 214-20. 
15 Wong SC, Chan CM, Ma BB et al. Clinical significance of cytokeratin 20-positive circulating 
tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer 
patients. Clinical Cancer Research 2009; 15: pp. 1005-12. 
16 Allen JE, El-Deiry WS. Circulating Tumor Cells and Colorectal Cancer. Current Cororectal 
Cancer Reports 2010; 6: pp. 212-20. 
Markers of circulating tumour cells expressed in melanoma patients, A. Reid et al. 
20 
 
17 Smith B, Selby P, Southgate J et al. Detection of melanoma cells in peripheral blood by 
means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338: pp. 1227-
9. 
18 Hoon DS, Wang Y, Dale PS et al. Detection of occult melanoma cells in blood with a multiple-
marker polymerase chain reaction assay. Journal of Clinical Oncology 1995; 13: pp. 2109-16. 
19 Brownbridge GG, Gold J, Edward M et al. Evaluation of the use of tyrosinase-specific and 
melanA/MART-1-specific reverse transcriptase-coupled--polymerase chain reaction to detect 
melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. 
The British Journal of Dematology 2001; 144: pp. 279-87. 
20 Reynolds SR, Albrecht J, Shapiro RL et al. Changes in the presence of multiple markers of 
circulating melanoma cells correlate with clinical outcome in patients with melanoma. 
Clinical Cancer Research 2003; 9: pp. 1497-502. 
21 Gkalpakiotis S, Arenberger P, Kremen J et al. Quantitative detection of melanoma-associated 
antigens by multimarker real-time RT-PCR for molecular staging: results of a 5 years study. 
Experimental Dermatology 2010; 19: pp. 994-9. 
22 Rao C, Bui T, Connelly M et al. Circulating melanoma cells and survival in metastatic 
melanoma. International Journal of Oncology 2011; 38: pp. 755-60. 
23 Ma J, Frank MH. Tumor initiation in human malignant melanoma and potential cancer 
therapies. Anti-cancer Agents in Medicinal Chemistry 2010; 10: pp. 131-6. 
24 Schatton T, Frank MH. Antitumor immunity and cancer stem cells. Annals of the New York 
Academy of Science 2009; 76: pp. 154-69. 
25 Koyanagi K, Kuo C, Nakagawa T et al. Multimarker quantitative real-time PCR detection of 
circulating melanoma cells in peripheral blood: relation to disease stage in melanoma 
patients. Clinical Chemistry 2005; 51: pp. 981-8. 
26 Parker KA, Glaysher S, Polak M et al. The molecular basis of the chemosensitivity of 
metastatic cutaneous melanoma to chemotherapy. Journal of Clinical Pathology 2010; 63: 
pp. 1012-20. 
27 Vachtenheim J, Novotná H. Expression of genes for microphthalmia isoforms, Pax3 and 
MSG1, in human melanomas. Cellular and molecular biology 1999; 45: pp. 1075-82. 
28 Coulie PG, Brichard V, Van Pel A et al. A new gene coding for a differentiation antigen 
recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. The journal of 
experimental medicine 1994; 180: pp. 35-42. 
29 Kokkinakis DM, Liu X, Chada S et al. Modulation of gene expression in human central 
nervous system tumors under methionine deprivation-induced stress. Cancer Research 
2004; 64: pp. 7513-25. 
30 Bardin N, Francès V, Lesaule G et al. Identification of the S-Endo 1 endothelial-associated 
antigen. Biochemical and Biophysical Research Communications 1996; 218: pp. 210-6. 
31 Frank NY, Pendse SS, Lapchak PH et al. Regulation of progenitor cell fusion by ABCB5 P-
glycoprotein, a novel human ATP-binding cassette transporter. The Journal of Biological 
Chemistry 2003; 278: pp. 47156-65. 
32 Medic S, Rizos H, Ziman M. Differential PAX3 functions in normal skin melanocytes and 
melanoma cells. Biochemical and Biophysical Research Communications 2011; 411: pp. 832-
7. 
33 Medic S, Ziman M. PAX3 across the spectrum: from melanoblast to melanoma. Critical 
Reviews in Biochemistry and Molecular Biology 2009; 44: pp. 85-97. 
34 Medic S, Ziman M. PAX3 expression in normal skin melanocytes and melanocytic lesions 
(naevi and melanomas). PLoS One 2010; 5: pp. e9977. 
35 Matsuzaki Y, Hashimoto S, Fujita T et al. Systematic identification of human melanoma 
antigens using serial analysis of gene expression (SAGE). Journal of Immunotherapy 2005; 28: 
pp. 10-9. 
Markers of circulating tumour cells expressed in melanoma patients, A. Reid et al. 
21 
 
36 Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 
414: pp.105-11. 
37 Koyanagi K, O'Day SJ, Boasberg P et al. Serial monitoring of circulating tumor cells predicts 
outcome of induction biochemotherapy plus maintenance biotherapy for metastatic 
melanoma. Clinical Cancer Research 2010; 16: pp. 2402-8. 
38 Rainen L, Oelmueller U, Jurgensen S et al. Stabilization of mRNA expression in whole blood 
samples. Clinical Chemistry 2002; 48: pp. 1883-90. 
39 Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over 
contamination in polymerase chain reactions. Gene 1990; 93: pp. 125-8. 
40 Giricz O, Lauer-Fields JL, Fields GB. The normalization of gene expression data in melanoma: 
investigating the use of glyceraldehyde 3-phosphate dehydrogenase and 18S ribosomal RNA 
as internal reference genes for quantitative real-time PCR. Analytical Biochemistry 2008; 
380: pp. 137-9. 
41 Tautz D, Renz M. An optimized freeze-squeeze method for the recovery of DNA fragments 
from agarose gels. Analytical Biochemistry 1983; 132: pp. 14-9. 
42 Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the 
circulation: Relation to Clinical stage, Surgical treatment, and recurrence from melanoma. 
Journal of Clinical Oncology 1998; 16: pp. 1760-9. 
43 Hoek K, Eichhoff O, Schlegel N et al. In vivo switching of human melanoma cells between 
proliferative and invasive states. Cancer Research 2008; 68: pp. 650-6. 
44 Husemann Y, Geigl JB, Schubert F et al. Systemic Spread Is an Early Step in Breast Cancer. 
Cancer Cell 2008; 13: pp. 58-68. 
45 Aubin F, Chtourou M, Teyssier JR et al. The detection of tyrosinase mRNA in the peripheral 
blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk 
and survival. Melanoma Research 2000; 10: pp. 113-8. 
46 Luca M, Hunt B, Bucana CD et al. Direct correlation between MUC18 expression and 
metastatic potential of human melanoma cells. Melanoma Research 1993; 3: pp. 35-41. 
 
 
 
 
 
Markers of circulating tumour cells expressed in melanoma patients, A. Reid et al. 
22 
 
Tables 
Table 1 – Number of markers detected in the peripheral blood of patients and healthy 
controls. 
Number of 
markers 
  % (n) 
0 1 2 3 4 5 n 
 
CMM Patients 8 (18) 20 (47) 34 (79) 23 (54) 10 (24) 3 (8) 230 
Healthy controls 41  (63) 41 (63) 11 (17) 4 (6) 2 (3) 0 152 
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Table 2 - qRT-PCR Marker detection in the peripheral blood of healthy controls and in 
melanoma patients categorised by AJCC stage. 
                  
 
AJCC staged melanoma patients % (n) 
Markers 0 I II III IV Healthy Controls 
MLANA 26 (10) 25 (19) 18 (7) 40 (12) 43 (20) 13 (19) 
ABCB5 
45 (17) 27 (21) 33 (13) 50 (15) 52 (24) 22 (33) 
Pax3d 47 (18) 30 (23) 36 (14) 50 (15) 46 (21) 14 (21) 
MCAM 42 (16) 49 (38) 46 (18) 53 (16) 43 (20) 14 (21) 
TGFβ2 63 (24) 64 (49) 74 (29) 77 (23) 59 (27) 22 (33) 
N 38 77 39 30 46 152 
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Table 3 - Melanoma patient characteristics 
Prognostic factor Number of patients 
Gender Males 
Females 
81 
149 
AJCC Stage 0 
I 
II 
III 
IV 
38 
77 
39 
30 
46 
Primary Site Face 
Torso 
Arms 
Legs 
Scalp 
No primary lesion or unknown 
36 
78 
31 
37 
14 
34 
Breslow thickness (primary) mm <1mm 
1-4mm 
>4mm 
Unknown 
103 
82 
20 
25 
Clark level I 
II 
III 
IV 
V 
Unknown 
43 
30 
20 
81 
15 
41 
Ulceration No 
Yes 
Unknown 
178 
34 
18 
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Table 4 - qRT-PCR Marker detection in the peripheral blood of melanoma patients 
categorised by recurrence and time since diagnosis. 
 
 
 
Patients with recurrence during study period      
% (n) 
Time since diagnosis in relation to sampling in 
patients with recurrence % (n) 
Markers recurrence no recurrence < 1 month < 1 year < 5 years > 5 years 
MLANA *45 (33) 23 (35) 33 (2) 18 (7) 26 (32) 22 (18) 
ABCB5 
*49 (36) 34 (54) 0 18 (7) 22 (27) 32 (26) 
Pax3d 41 (30) 39 (61) 33 (2) 21 (8) 22 (27) 15 (12) 
MCAM 49 (36) 46 (72) 0 21 (8) 21 (26) 25 (25) 
TGFβ2 63 (46) 68 (106) 50 (3) 29 (11) 34 (42) 34 (34) 
N 73 157 6 38 124 81 
P-value* - Pearson chi-square test, p<0.01                     
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Table 5 – MCAM expression in the peripheral blood of stage IV melanoma patients in 
relation to clinical outcome. 
 
 MCAM expression % (n)  
Clinical Outcome + - N 
Negative (disease progression and/or death) 43 (17) 58 (23) 40 
Positive (disease remained stable or tumour size reduced) 9 (2) 91 (20) 22 
  
